PCM
AMRX icon

Penn Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Penn Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.5M Sell
1,181,176
-14,897
-1% -$204K 1.3% 27
2026
Q1 		$14.9M Buy
1,196,073
+194,122
+19% +$2.61M 1.15% 45
2025
Q4 		$12.7M Buy
+1,001,951
New +$11.5M 1.01% 56

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Penn Capital Management's AMRX Position: Q2 2026 in Review

Penn Capital Management reduced its Amneal Pharmaceuticals (AMRX) stake by 1.2% in Q2 2026, selling an estimated $204K and leaving 1,181,176 shares worth $20.5M. The position accounts for 1.3% of the portfolio, ranked #27.

Penn Capital Management first reported a position in AMRX in Q4 2025 and has held it in 3 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Penn Capital Management held 1,181,176 shares of Amneal Pharmaceuticals worth $20.5M as of Q2 2026.
  • Penn Capital Management sold 14,897 Amneal Pharmaceuticals shares in Q2 2026, an estimated $204K.
  • Amneal Pharmaceuticals made up 1.3% of Penn Capital Management's portfolio in Q2 2026, its #27 holding.
  • Penn Capital Management first reported a position in Amneal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.